STING1 and neoplasm: Activating cGAS-STING signaling with small molecule drugs can trigger relevant innate immune signals, activating various immune cells, including dendritic cells, macrophages, NK cells, and CD4+ and CD8+ T cells, resulting in significant tumor shrinkage or even complete regression in vivo (107).